search
Back to results

CPI-006 Plus Standard of Care Versus Placebo Plus Standard of Care in Mild to Moderately Symptomatic Hospitalized Covid-19 Patients

Primary Purpose

Covid-19

Status
Terminated
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
CPI-006 2 mg/kg + SOC
CPI-006 1 mg/kg + SOC
Placebo + SOC
Sponsored by
Corvus Pharmaceuticals, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Covid-19 focused on measuring SARS-CoV-2, Covid, Coronavirus, Covid19, COVID-19

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Confirmed positive by polymerase chain reaction (PCR) or antigen test for SARS-CoV-2 with sample collection ≤ 10 days prior to randomization
  • Covid-19 illness of any duration of symptoms
  • Hospitalized for Covid-19 for ≤ 5 days with mild to moderate Covid-19 symptoms and meets criteria for either Category 4, Category 5, or Category 6 per 8-point ordinal scale
  • Adequate organ function
  • Participants of child-bearing age must agree to use adequate contraception for 6 weeks after study treatment administration

Exclusion Criteria:

  • Signs of acute respiratory distress syndrome or respiratory failure necessitating mechanical ventilation at time of screening/randomization or anticipated need for mechanical ventilation
  • History of severe chronic respiratory disease and requirement for long-term oxygen therapy
  • Uncontrolled active systemic infection or hemodynamic instability requiring admission to an intensive care unit
  • Malignant tumor receiving treatment, or other serious systemic diseases affecting life expectancy within 29 days of screening
  • Receipt of cancer chemotherapy or immunomodulatory drugs during preceding 2 months (steroids for treatment of Covid-19 are acceptable)
  • Convalescent plasma (CCP) or anti-SARS-CoV-2 monoclonal antibodies administered <24 hours prior to randomization. Must have recovered from any adverse events related to CCP treatment. Received chloroquine or hydroxychloroquine within last 7 days or during the study
  • Current participation in other clinical trials including extended access programs
  • Active deep vein thrombosis or pulmonary embolism within last 6 months
  • Anticipated discharge from hospital or transfer to another hospital which is not a study site within 48 hours of admission
  • Active uncontrolled co-morbid disease that may interfere with study conduct or interpretation of findings
  • Known to be positive for HIV or positive test for chronic HBV infection or positive test for hepatitis C antibody
  • Pregnancy or breast feeding

Sites / Locations

  • Sharp Chula Vista Medical Center
  • El Centro Regional Medical Center
  • Sharp Grossmont Hospital
  • Torrance Memorial Medical Center
  • Mayo Clinic - Jacksonville
  • Cambridge Medical Trials
  • MedPharmics
  • Holy Cross Hospital
  • Mayo Clinic - Rochester
  • Stony Brook University Medical Center
  • Cape Fear Valley Medical Center
  • Lehigh Valley Health Network
  • Temple University Hospital
  • Clinica Zabala
  • Clínica Adventista Belgrano
  • Instituto Medico Platense
  • Clinica Independencia
  • Instituto Médico Río Cuarto
  • Centro de Investigación Clínica - Clínica Viedma
  • Centro Médico IPAM
  • Hospital Provincial Del Centenario
  • Clinica Mayo de U.M.C.B. S.R.L
  • Hospital de Clínicas Presidente Dr. Nicolás Avellaneda
  • Fundación Sanatorio Güemes
  • Sanatorio Finochietto
  • Hospital Rawson
  • Hospital Vera Cruz
  • Hospital Agamenon Magalhães
  • Santa Casa de Porto Alegre
  • Hospital Dia do Pulmão
  • Clínica Supera
  • Centro Hospitalar Nossa Saúde
  • Universidade Municipal São Caetano do Sul
  • Conjunto Hospitalar do Mandaqui
  • Hospital Anchieta
  • Hospital de Base Da Faculdade de Medicina de São José Do Rio Preto
  • Hospital E Maternidade Celso Pierro PUCCAMP
  • Universidade Federal Do Espirito Santo - Hospital Universitário Cassiano Antônio de Moraes - HUCAM
  • Toronto General Hospital
  • Hôpital Maisonneuve-Rosemont
  • Hospital Base de Osorno
  • Clinica Vespucio
  • Research Network Consulting
  • Clínica Dávila Y Servicios Médicos SA
  • Rodrigo Botero S.A.S
  • Fundacion Santa Fe de Bogota
  • Clínica Universidad De la Sabana
  • Fundacion Centro de Excelencia en Enfermedades Cronicas No Transmisibles
  • Clínica de la Mujer S.A.S.
  • Hospital Universitario Clinica San Rafael
  • Fundacion Hospitalaria San Vicente de Paul
  • Promotora Medica Las Américas S.A- Clínica Las Américas
  • Fundación Valle Del Lili
  • Medizinische Hochschule Hannover
  • Azienda Ospedaliera Cotugno
  • ASST Fatebenefratelli Sacco - Ospedale Luigi Sacco
  • ASST Grande Ospedale Metropolitano Niguarda - Presidio Ospedaliero Ospedale Niguarda Ca' Granda
  • ASST Santi Paolo e Carlo - Azienda Universitaria-Polo Universitario San Paolo
  • Ospedale San Raffaele S.r.l.
  • ASST di Monza - Azienda Ospedaliera San Gerardo
  • Fondazione IRCCS Policlinico San Matteo di Pavia
  • ASST della Valle Olona - Azienda Ospedaliera Ospedale Di Circolo Di Busto Arsizio
  • Hospital Civil Fray Antonio Alcalde
  • Hospital Universitario Dr. Jose Eleuterio González
  • Hospital Civil de Culiacán
  • Hospital General de Culiacán
  • Hospital Nacional Sergio E. Bernales
  • Hospital Chancay y Servicios Basicos de Salud
  • Hospital Central Fuerza Aérea del Perú
  • Hospital María Auxiliadora
  • Clínica Providencia
  • Clínica San Pablo
  • Hospital Alberto Sabogal Sologuren
  • Hospital Nacional Adolfo Guevara Velasco Essalud
  • Hospital Militar Central
  • Hospital Nacional Guillermo Almenara Irigoyen
  • Hospital Costa del Sol
  • Complejo Hospitalario de Navarra
  • Hospital del Mar
  • Hospital General Universitario de Guadalajara
  • Complejo Asistencial Universitario de Salamanca - H. Clinico
  • Hospital Universitario A Coruña
  • Municipal Institution City Clinical Hospital #6 of Dnipropetrovsk Regional Council
  • Kharkiv Regional Clinical Infectious Diseases Hospital
  • Poltava Regional Clinical Infectious Hospital
  • Communal Non-Commercial Enterprise Vinnytsia City Clinical Hospital 1
  • Municipal enterprise Volyn Regional Clinical Hospital of Volyn Regional Council
  • MNPE City Hospital No. 6 of Zaporizhzhia City Council
  • Municipal Institution City Hospital #7
  • CNPE City Clinical Hospital #3 of Chernivtsi City Council
  • Municipal Non-profit Enterprise "City Clinical Hospital # 4" of Dnipro City Council

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Placebo Comparator

Arm Label

CPI-006 (2 mg/kg) Plus Standard of Care

CPI-006 (1 mg/kg) Plus Standard of Care

Placebo Plus Standard of Care

Arm Description

Participants will receive a single dose of CPI-006 at 2 mg/kg up to a maximum dose of 200 mg intravenously on Day 1 plus standard of care.

Participants will receive a single dose of CPI-006 at 1 mg/kg up to a maximum dose of 100 mg intravenously on Day 1 plus standard of care.

Participants will receive a single dose of placebo intravenously on Day 1 plus standard of care.

Outcomes

Primary Outcome Measures

Proportion of Participants Alive and Respiratory Failure Free of CPI-006 Plus SOC Versus Placebo Plus SOC
Proportion of participants who are alive and free from respiratory deterioration in each active arm compared to placebo arm as measured by the modified World Health Organization (WHO) 8-point Ordinal Scale for Clinical Improvement in which: 1=Not hospitalized, no limitations on activities; 2=Not hospitalized, limitation on activities and/or requiring home oxygen; 3=Hospitalized, not requiring supplemental oxygen - no longer requiring ongoing medical care; 4=Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (Covid-19 related or otherwise); 5=Hospitalized, requiring supplemental oxygen; 6=Hospitalized, on non-invasive ventilation or high flow oxygen devices; 7=Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation; 8=Death.

Secondary Outcome Measures

Time to Recovery of CPI-006 Plus SOC Versus Placebo Plus SOC
Time to recovery after dosing in each active arm compared to placebo arm as measured by the modified WHO 8-point Ordinal Scale for Clinical Improvement in which: 1=Not hospitalized, no limitations on activities; 2=Not hospitalized, limitation on activities and/or requiring home oxygen; 3=Hospitalized, not requiring supplemental oxygen - no longer requiring ongoing medical care; 4=Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (Covid-19 related or otherwise); 5=Hospitalized, requiring supplemental oxygen; 6=Hospitalized, on non-invasive ventilation or high flow oxygen devices; 7=Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation; 8=Death.
Time to Clinical Improvement of CPI-006 Plus SOC Versus Placebo Plus SOC
Time to clinical improvement in each active arm compared to placebo arm as measured by the modified WHO 8-point Ordinal Scale for Clinical Improvement in which: 1=Not hospitalized, no limitations on activities; 2=Not hospitalized, limitation on activities and/or requiring home oxygen; 3=Hospitalized, not requiring supplemental oxygen - no longer requiring ongoing medical care; 4=Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (Covid-19 related or otherwise); 5=Hospitalized, requiring supplemental oxygen; 6=Hospitalized, on non-invasive ventilation or high flow oxygen devices; 7=Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation; 8=Death. Clinical improvement is defined as ≥ 2 points improvement in the 8-point ordinal scale.
Mortality Rate Due to Any Cause of CPI-006 Plus SOC Versus Placebo Plus SOC
Proportion of participants who died in each active arm compared to placebo arm

Full Information

First Posted
January 29, 2021
Last Updated
September 7, 2022
Sponsor
Corvus Pharmaceuticals, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT04734873
Brief Title
CPI-006 Plus Standard of Care Versus Placebo Plus Standard of Care in Mild to Moderately Symptomatic Hospitalized Covid-19 Patients
Official Title
Phase 3, Randomized, Placebo Controlled, Double-blind, Multicenter, Stratified Study of CPI-006 Plus Standard of Care Versus Placebo Plus Standard of Care in Mild to Moderately Symptomatic Hospitalized Covid-19 Patients
Study Type
Interventional

2. Study Status

Record Verification Date
September 2022
Overall Recruitment Status
Terminated
Why Stopped
Sponsor decision. Not related to safety issues.
Study Start Date
February 25, 2021 (Actual)
Primary Completion Date
August 18, 2021 (Actual)
Study Completion Date
August 18, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Corvus Pharmaceuticals, Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This is a phase 3, randomized, placebo controlled, double-blind, multicenter, stratified study of CPI-006 plus standard of care (SOC) versus placebo plus SOC in mild to moderately symptomatic hospitalized Covid-19 patients with the primary objective to compare the proportion of participants alive and respiratory failure free between CPI-006 plus SOC versus placebo plus SOC.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Covid-19
Keywords
SARS-CoV-2, Covid, Coronavirus, Covid19, COVID-19

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
46 (Actual)

8. Arms, Groups, and Interventions

Arm Title
CPI-006 (2 mg/kg) Plus Standard of Care
Arm Type
Experimental
Arm Description
Participants will receive a single dose of CPI-006 at 2 mg/kg up to a maximum dose of 200 mg intravenously on Day 1 plus standard of care.
Arm Title
CPI-006 (1 mg/kg) Plus Standard of Care
Arm Type
Experimental
Arm Description
Participants will receive a single dose of CPI-006 at 1 mg/kg up to a maximum dose of 100 mg intravenously on Day 1 plus standard of care.
Arm Title
Placebo Plus Standard of Care
Arm Type
Placebo Comparator
Arm Description
Participants will receive a single dose of placebo intravenously on Day 1 plus standard of care.
Intervention Type
Drug
Intervention Name(s)
CPI-006 2 mg/kg + SOC
Intervention Description
IV CPI-006 2 mg/kg up to a maximum dose of 200 mg plus standard of care
Intervention Type
Drug
Intervention Name(s)
CPI-006 1 mg/kg + SOC
Intervention Description
IV CPI-006 1 mg/kg up to a maximum dose of 100 mg plus standard of care
Intervention Type
Drug
Intervention Name(s)
Placebo + SOC
Intervention Description
IV placebo plus standard of care
Primary Outcome Measure Information:
Title
Proportion of Participants Alive and Respiratory Failure Free of CPI-006 Plus SOC Versus Placebo Plus SOC
Description
Proportion of participants who are alive and free from respiratory deterioration in each active arm compared to placebo arm as measured by the modified World Health Organization (WHO) 8-point Ordinal Scale for Clinical Improvement in which: 1=Not hospitalized, no limitations on activities; 2=Not hospitalized, limitation on activities and/or requiring home oxygen; 3=Hospitalized, not requiring supplemental oxygen - no longer requiring ongoing medical care; 4=Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (Covid-19 related or otherwise); 5=Hospitalized, requiring supplemental oxygen; 6=Hospitalized, on non-invasive ventilation or high flow oxygen devices; 7=Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation; 8=Death.
Time Frame
During the 28 days after dosing
Secondary Outcome Measure Information:
Title
Time to Recovery of CPI-006 Plus SOC Versus Placebo Plus SOC
Description
Time to recovery after dosing in each active arm compared to placebo arm as measured by the modified WHO 8-point Ordinal Scale for Clinical Improvement in which: 1=Not hospitalized, no limitations on activities; 2=Not hospitalized, limitation on activities and/or requiring home oxygen; 3=Hospitalized, not requiring supplemental oxygen - no longer requiring ongoing medical care; 4=Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (Covid-19 related or otherwise); 5=Hospitalized, requiring supplemental oxygen; 6=Hospitalized, on non-invasive ventilation or high flow oxygen devices; 7=Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation; 8=Death.
Time Frame
During the 28 days after dosing
Title
Time to Clinical Improvement of CPI-006 Plus SOC Versus Placebo Plus SOC
Description
Time to clinical improvement in each active arm compared to placebo arm as measured by the modified WHO 8-point Ordinal Scale for Clinical Improvement in which: 1=Not hospitalized, no limitations on activities; 2=Not hospitalized, limitation on activities and/or requiring home oxygen; 3=Hospitalized, not requiring supplemental oxygen - no longer requiring ongoing medical care; 4=Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (Covid-19 related or otherwise); 5=Hospitalized, requiring supplemental oxygen; 6=Hospitalized, on non-invasive ventilation or high flow oxygen devices; 7=Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation; 8=Death. Clinical improvement is defined as ≥ 2 points improvement in the 8-point ordinal scale.
Time Frame
During the 28 days after dosing
Title
Mortality Rate Due to Any Cause of CPI-006 Plus SOC Versus Placebo Plus SOC
Description
Proportion of participants who died in each active arm compared to placebo arm
Time Frame
During the 28 days after dosing

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Confirmed positive by polymerase chain reaction (PCR) or antigen test for SARS-CoV-2 with sample collection ≤ 10 days prior to randomization Covid-19 illness of any duration of symptoms Hospitalized for Covid-19 for ≤ 5 days with mild to moderate Covid-19 symptoms and meets criteria for either Category 4, Category 5, or Category 6 per 8-point ordinal scale Adequate organ function Participants of child-bearing age must agree to use adequate contraception for 6 weeks after study treatment administration Exclusion Criteria: Signs of acute respiratory distress syndrome or respiratory failure necessitating mechanical ventilation at time of screening/randomization or anticipated need for mechanical ventilation History of severe chronic respiratory disease and requirement for long-term oxygen therapy Uncontrolled active systemic infection or hemodynamic instability requiring admission to an intensive care unit Malignant tumor receiving treatment, or other serious systemic diseases affecting life expectancy within 29 days of screening Receipt of cancer chemotherapy or immunomodulatory drugs during preceding 2 months (steroids for treatment of Covid-19 are acceptable) Convalescent plasma (CCP) or anti-SARS-CoV-2 monoclonal antibodies administered <24 hours prior to randomization. Must have recovered from any adverse events related to CCP treatment. Received chloroquine or hydroxychloroquine within last 7 days or during the study Current participation in other clinical trials including extended access programs Active deep vein thrombosis or pulmonary embolism within last 6 months Anticipated discharge from hospital or transfer to another hospital which is not a study site within 48 hours of admission Active uncontrolled co-morbid disease that may interfere with study conduct or interpretation of findings Known to be positive for HIV or positive test for chronic HBV infection or positive test for hepatitis C antibody Pregnancy or breast feeding
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
S. Mahabhashyam, MD, MPH
Organizational Affiliation
Corvus Pharmaceuticals
Official's Role
Study Chair
Facility Information:
Facility Name
Sharp Chula Vista Medical Center
City
Chula Vista
State/Province
California
ZIP/Postal Code
91911
Country
United States
Facility Name
El Centro Regional Medical Center
City
El Centro
State/Province
California
ZIP/Postal Code
92243
Country
United States
Facility Name
Sharp Grossmont Hospital
City
La Mesa
State/Province
California
ZIP/Postal Code
91942
Country
United States
Facility Name
Torrance Memorial Medical Center
City
Torrance
State/Province
California
ZIP/Postal Code
90505
Country
United States
Facility Name
Mayo Clinic - Jacksonville
City
Jacksonville
State/Province
Florida
ZIP/Postal Code
32224
Country
United States
Facility Name
Cambridge Medical Trials
City
Alexandria
State/Province
Louisiana
ZIP/Postal Code
71301
Country
United States
Facility Name
MedPharmics
City
Metairie
State/Province
Louisiana
ZIP/Postal Code
70006
Country
United States
Facility Name
Holy Cross Hospital
City
Silver Spring
State/Province
Maryland
ZIP/Postal Code
20910
Country
United States
Facility Name
Mayo Clinic - Rochester
City
Rochester
State/Province
Minnesota
ZIP/Postal Code
55905
Country
United States
Facility Name
Stony Brook University Medical Center
City
Stony Brook
State/Province
New York
ZIP/Postal Code
11794
Country
United States
Facility Name
Cape Fear Valley Medical Center
City
Fayetteville
State/Province
North Carolina
ZIP/Postal Code
28304
Country
United States
Facility Name
Lehigh Valley Health Network
City
Allentown
State/Province
Pennsylvania
ZIP/Postal Code
18103
Country
United States
Facility Name
Temple University Hospital
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19140
Country
United States
Facility Name
Clinica Zabala
City
Ciudad Autónoma de Buenos Aires
State/Province
Buenos Aires
Country
Argentina
Facility Name
Clínica Adventista Belgrano
City
Estomba
State/Province
Buenos Aires
Country
Argentina
Facility Name
Instituto Medico Platense
City
La Plata
State/Province
Buenos Aires
Country
Argentina
Facility Name
Clinica Independencia
City
Munro
State/Province
Buenos Aires
Country
Argentina
Facility Name
Instituto Médico Río Cuarto
City
Río Cuarto
State/Province
Córdoba
Country
Argentina
Facility Name
Centro de Investigación Clínica - Clínica Viedma
City
Viedma
State/Province
Río Negro
Country
Argentina
Facility Name
Centro Médico IPAM
City
Rosario
State/Province
Santa Fe
Country
Argentina
Facility Name
Hospital Provincial Del Centenario
City
Rosario
State/Province
Santa Fe
Country
Argentina
Facility Name
Clinica Mayo de U.M.C.B. S.R.L
City
San Miguel de Tucumán
State/Province
Tucumán
Country
Argentina
Facility Name
Hospital de Clínicas Presidente Dr. Nicolás Avellaneda
City
San Miguel De Tucumán
State/Province
Tucumán
Country
Argentina
Facility Name
Fundación Sanatorio Güemes
City
Ciudad Autónoma de Buenos Aires
Country
Argentina
Facility Name
Sanatorio Finochietto
City
Ciudad Autónoma de Buenos Aires
Country
Argentina
Facility Name
Hospital Rawson
City
Córdoba
Country
Argentina
Facility Name
Hospital Vera Cruz
City
Belo Horizonte
State/Province
Minas Gerais
Country
Brazil
Facility Name
Hospital Agamenon Magalhães
City
Recife
State/Province
Pernambuco
Country
Brazil
Facility Name
Santa Casa de Porto Alegre
City
Porto Alegre
State/Province
Rio Grande Do Sul
Country
Brazil
Facility Name
Hospital Dia do Pulmão
City
Blumenau
State/Province
Santa Catarina
Country
Brazil
Facility Name
Clínica Supera
City
Chapecó
State/Province
Santa Catarina
Country
Brazil
Facility Name
Centro Hospitalar Nossa Saúde
City
Curitiba
Country
Brazil
Facility Name
Universidade Municipal São Caetano do Sul
City
São Caetano do Sul
Country
Brazil
Facility Name
Conjunto Hospitalar do Mandaqui
City
São Paulo
Country
Brazil
Facility Name
Hospital Anchieta
City
São Paulo
Country
Brazil
Facility Name
Hospital de Base Da Faculdade de Medicina de São José Do Rio Preto
City
São Paulo
Country
Brazil
Facility Name
Hospital E Maternidade Celso Pierro PUCCAMP
City
São Paulo
Country
Brazil
Facility Name
Universidade Federal Do Espirito Santo - Hospital Universitário Cassiano Antônio de Moraes - HUCAM
City
Vitória
Country
Brazil
Facility Name
Toronto General Hospital
City
Toronto
State/Province
Ontario
Country
Canada
Facility Name
Hôpital Maisonneuve-Rosemont
City
Montréal
State/Province
Quebec
ZIP/Postal Code
H1T 2M4
Country
Canada
Facility Name
Hospital Base de Osorno
City
Concepción
Country
Chile
Facility Name
Clinica Vespucio
City
La Florida
Country
Chile
Facility Name
Research Network Consulting
City
Linares
Country
Chile
Facility Name
Clínica Dávila Y Servicios Médicos SA
City
Santiago
Country
Chile
Facility Name
Rodrigo Botero S.A.S
City
Medellín
State/Province
Antioquia
Country
Colombia
Facility Name
Fundacion Santa Fe de Bogota
City
Bogotá
State/Province
Cundinamarca
Country
Colombia
Facility Name
Clínica Universidad De la Sabana
City
Chía
State/Province
Cundinamarca
Country
Colombia
Facility Name
Fundacion Centro de Excelencia en Enfermedades Cronicas No Transmisibles
City
Monteria
State/Province
Córdoba
Country
Colombia
Facility Name
Clínica de la Mujer S.A.S.
City
Bogotá
Country
Colombia
Facility Name
Hospital Universitario Clinica San Rafael
City
Bogotá
Country
Colombia
Facility Name
Fundacion Hospitalaria San Vicente de Paul
City
Medellín
Country
Colombia
Facility Name
Promotora Medica Las Américas S.A- Clínica Las Américas
City
Medellín
Country
Colombia
Facility Name
Fundación Valle Del Lili
City
Santiago de Cali
Country
Colombia
Facility Name
Medizinische Hochschule Hannover
City
Hannover
State/Province
Niedersachsen
Country
Germany
Facility Name
Azienda Ospedaliera Cotugno
City
Napoli
State/Province
Campania
Country
Italy
Facility Name
ASST Fatebenefratelli Sacco - Ospedale Luigi Sacco
City
Milano
State/Province
Lombardia
Country
Italy
Facility Name
ASST Grande Ospedale Metropolitano Niguarda - Presidio Ospedaliero Ospedale Niguarda Ca' Granda
City
Milano
State/Province
Lombardia
Country
Italy
Facility Name
ASST Santi Paolo e Carlo - Azienda Universitaria-Polo Universitario San Paolo
City
Milano
State/Province
Lombardia
Country
Italy
Facility Name
Ospedale San Raffaele S.r.l.
City
Milano
State/Province
Lombardia
Country
Italy
Facility Name
ASST di Monza - Azienda Ospedaliera San Gerardo
City
Monza
State/Province
Lombardia
Country
Italy
Facility Name
Fondazione IRCCS Policlinico San Matteo di Pavia
City
Pavia
State/Province
Lombardia
Country
Italy
Facility Name
ASST della Valle Olona - Azienda Ospedaliera Ospedale Di Circolo Di Busto Arsizio
City
Busto Arsizio
Country
Italy
Facility Name
Hospital Civil Fray Antonio Alcalde
City
Guadalajara
State/Province
Jalisco
Country
Mexico
Facility Name
Hospital Universitario Dr. Jose Eleuterio González
City
Monterrey
State/Province
Nuevo Leon
Country
Mexico
Facility Name
Hospital Civil de Culiacán
City
Culiacán
State/Province
Sinaloa
Country
Mexico
Facility Name
Hospital General de Culiacán
City
Culiacán
State/Province
Sinaloa
Country
Mexico
Facility Name
Hospital Nacional Sergio E. Bernales
City
Comas
State/Province
Lima
Country
Peru
Facility Name
Hospital Chancay y Servicios Basicos de Salud
City
Huaral
State/Province
Lima
Country
Peru
Facility Name
Hospital Central Fuerza Aérea del Perú
City
Miraflores
State/Province
Lima
Country
Peru
Facility Name
Hospital María Auxiliadora
City
San Juan De Miraflores
State/Province
Lima
Country
Peru
Facility Name
Clínica Providencia
City
San Miguel
State/Province
Lima
Country
Peru
Facility Name
Clínica San Pablo
City
Santiago De Surco
State/Province
Lima
Country
Peru
Facility Name
Hospital Alberto Sabogal Sologuren
City
Callao
Country
Peru
Facility Name
Hospital Nacional Adolfo Guevara Velasco Essalud
City
Cusco
Country
Peru
Facility Name
Hospital Militar Central
City
Lima
Country
Peru
Facility Name
Hospital Nacional Guillermo Almenara Irigoyen
City
Lima
Country
Peru
Facility Name
Hospital Costa del Sol
City
Marbella
State/Province
Málaga
Country
Spain
Facility Name
Complejo Hospitalario de Navarra
City
Pamplona
State/Province
Navarra
Country
Spain
Facility Name
Hospital del Mar
City
Barcelona
Country
Spain
Facility Name
Hospital General Universitario de Guadalajara
City
Guadalajara
Country
Spain
Facility Name
Complejo Asistencial Universitario de Salamanca - H. Clinico
City
Salamanca
Country
Spain
Facility Name
Hospital Universitario A Coruña
City
Santiago de Compostela
Country
Spain
Facility Name
Municipal Institution City Clinical Hospital #6 of Dnipropetrovsk Regional Council
City
Dnipro
State/Province
Dnipropetrovs'ka Oblast
Country
Ukraine
Facility Name
Kharkiv Regional Clinical Infectious Diseases Hospital
City
Kharkiv
State/Province
Kharkivs'ka Oblast
Country
Ukraine
Facility Name
Poltava Regional Clinical Infectious Hospital
City
Poltava
State/Province
Poltavs'ka Oblast
Country
Ukraine
Facility Name
Communal Non-Commercial Enterprise Vinnytsia City Clinical Hospital 1
City
Vinnytsya
State/Province
Vinnytsia Oblast
Country
Ukraine
Facility Name
Municipal enterprise Volyn Regional Clinical Hospital of Volyn Regional Council
City
Lutsk
State/Province
Volyn Oblast
Country
Ukraine
Facility Name
MNPE City Hospital No. 6 of Zaporizhzhia City Council
City
Zaporizhzhia
State/Province
Zaporiz'ka Oblast
Country
Ukraine
Facility Name
Municipal Institution City Hospital #7
City
Zhaporizhzhya
State/Province
Zaporiz'ka Oblast
Country
Ukraine
Facility Name
CNPE City Clinical Hospital #3 of Chernivtsi City Council
City
Chernivtsi
Country
Ukraine
Facility Name
Municipal Non-profit Enterprise "City Clinical Hospital # 4" of Dnipro City Council
City
Dnipro
Country
Ukraine

12. IPD Sharing Statement

Learn more about this trial

CPI-006 Plus Standard of Care Versus Placebo Plus Standard of Care in Mild to Moderately Symptomatic Hospitalized Covid-19 Patients

We'll reach out to this number within 24 hrs